--- schema_version: "secwatch.filing_event.v1" accession: "0000950170-23-050440" form_type: "8-K" ticker: "KALV" cik: "0001348911" company_name: "KalVista Pharmaceuticals, Inc." filed_at: "2023-09-28T23:59:59+00:00" generated_at: "2026-06-10T07:31:13.305146+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.3 calibrated_materiality_score: 0.3 confidence: "high" source: SEC EDGAR --- # KalVista stockholders approve officer exculpation amendment, elect directors ## Summary - Approved certificate of amendment to limit officer liability under Delaware law (20.2M for, 2.5M against). - Elected Patrick Treanor and Edward W. Unkart as Class II directors for three-year terms. - Ratified Deloitte & Touche as independent auditor for FY ending April 30, 2024 (30.8M for, 1.6K against). - Non-binding advisory vote on named executive officer compensation passed (20.0M for, 2.7M against). ## SEC filing metadata - accession: 0000950170-23-050440 - form_type: 8-K - ticker: KALV - cik: 0001348911 - company_name: KalVista Pharmaceuticals, Inc. - filed_at: 2023-09-28T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.3 - calibrated_materiality_score: 0.3 - confidence: high - sec_items: 5.03, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/0000950170-23-050440-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/kalv-20230926.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000950170-23-050440 - JSON: https://secwatch.observer/filing/0000950170-23-050440.json - Plain text: https://secwatch.observer/filing/0000950170-23-050440.txt ## Key facts - Governance Changes KalVista Pharmaceuticals, Inc.: Certificate of amendment to certificate of incorporation to permit exculpation of certain officers from liability in specific circumstances (effective 2023-09-26). - Change: charter amendment - Effective: 2023-09-26 source text: the Company’s stockholders approved a certificate of amendment (the “Certificate of Amendment”) to the Company’s certificate of incorporation to permit the exculpation of certain of the Company’s officers from liability in specific circumstances. evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/0000950170-23-050440-index.htm - Shareholder Votes KalVista Pharmaceuticals, Inc. shareholders approved Approval of the Certificate of Amendment to limit the liability of certain officers of the company as permitted pursuant to recent amendments to the Delaware General Corporation Law at the 2023-09-26 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2023-09-26 source text: 4. Approval of the Certificate of Amendment to limit the liability of certain officers of the company as permitted pursuant to recent amendments to the Delaware General Corporation Law: Shares For Shares Against Shares Abstaining Broker Non-Votes 20,203,486 2,450,421 1,385 8,184,921 evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/0000950170-23-050440-index.htm - Shareholder Votes KalVista Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024 at the 2023-09-26 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-09-26 source text: 2. Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024: Shares For Shares Against Shares Abstaining Broker Non-Votes 30,837,741 1,624 848 N/A evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/0000950170-23-050440-index.htm - Shareholder Votes KalVista Pharmaceuticals, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers at the 2023-09-26 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-09-26 source text: 3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers: Shares For Shares Against Shares Abstaining Broker Non-Votes 20,001,348 2,652,134 1,810 8,184,921 evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/0000950170-23-050440-index.htm - Shareholder Votes KalVista Pharmaceuticals, Inc. shareholders approved Election of two Class II directors at the 2023-09-26 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-09-26 source text: On September 26, 2023, the Company held its 2023 Annual Meeting of Stockholders (“ Annual Meeting ”) and the following proposals were adopted: 1. Election of two Class II directors, Patrick Treanor and Edward W. Unkart (each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified): Nominees Shares For Shares Against Shares Abstaining Broker Non-Votes Patrick Treanor 15,931,760 6,722,475 1,058 8,184,920 Edward W. Unkart 15,154,122 7,499,378 1,791 8,184,922 evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/0000950170-23-050440-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.